Board of Directors

Robert J. Coury is the executive chairman of Mylan's board of directors. Under his leadership, Mylan has been transformed into one of the largest generics and specialty pharmaceutical companies in the world, serving customers in approximately 150 countries and territories.

Coury was elected to Mylan's board of directors in February 2002, having served since 1995 as a strategic advisor to the company. He became the board's vice chairman shortly after his election and was made CEO of the company in September of that same year, a post he held through 2011.

In 2007, Mylan, under Coury's leadership, went from a U.S. focused company, to a global powerhouse. At the time, Mylan was the third largest generics manufacturer in the U.S. By purchasing India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and acquiring the generics business of Europe-based Merck KGaA, Mylan catapulted to the No. 3 position in the industry worldwide. The acquisition of the former "Merck Generics" gave the company unprecedented scale in many critical areas, including an extensive and unique international commercial footprint.

Prior to these game-changing acquisitions, from 2002-2007, Coury helped further position Mylan to prosper long-term in a consolidating industry marked by increasing competition and growing demand worldwide for high quality, affordable pharmaceuticals. During this pre-globalization period, the company more than doubled its manufacturing capacity; expanded investment in research and development; and maintained Mylan's strong industry leadership on key issues, working with policymakers to help create a more level playing field for producers of generic drugs.

Before Mylan, Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm. Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.